News

OPPI at 60: Pharma industry calls for stronger partnerships to propel India into global innovation leadership

  • By IPP Bureau | November 20, 2026
India must move beyond its traditional strength as the ‘Pharmacy of the World’ and emerge as a global powerhouse of pharmaceutical innovation, research and high-value capabilities.
 
Industry leaders and policymakers have said these in unison at the Organisation of Pharmaceutical Producers of India’s (OPPI) Annual Summit 2026 in New Delhi.
 
Marking 60 years of engagement with India's healthcare ecosystem, the summit brought together senior government officials, regulators, pharmaceutical industry leaders, academia and healthcare stakeholders under the theme ‘Power of Partnerships’.
 
The central message was clear: India's next pharmaceutical growth story will depend not just on manufacturing scale, but on stronger collaboration between government, industry and academia, greater research investments and a regulatory environment that encourages innovation.
 
Amitabh Dube, President – OPPI and Country President and Managing Director, Novartis India said, “India has established strong foundations in pharmaceutical manufacturing, talent and science. The opportunity ahead is to build on these strengths and move towards greater innovation, research and high-value capabilities. 
 
"This transition will require partnerships across government, industry, academia and the wider healthcare ecosystem. As OPPI celebrates 60 years, the theme ‘Power of Partnerships’ reflects the collective effort needed to advance India's pharmaceutical ambitions.”
 
Anil Matai, Director General, OPPI said, “India's pharmaceutical ambitions require an ecosystem that supports research, encourages investment and provides regulatory predictability. Timely access to innovative medicines and stronger research capabilities will be important to this journey. 
 
"The three publications launched at the Summit bring together perspectives on India's healthcare ambitions, the evolving role of Pharma GCCs and Regulatory Data Protection. OPPI remains committed to constructive engagement with policymakers and stakeholders to advance these priorities, keeping patients and better health outcomes at the centre.”
 
Three reports outline India's pharmaceutical growth agenda
 
A major highlight of the summit was the launch of three publications examining the opportunities and policy priorities shaping India's pharmaceutical future.
 
The publications were:
 
OPPI at 60: The Power of Partnerships – Powering India's Healthcare Century: Driving Innovation, Resilience and Better Health Outcomes.
Pharma GCCs: Powering India's Next Growth Frontier.
Advancing Pharmaceutical Innovation in India through Regulatory Data Protection.
 
The first report examines India's transition from the ‘Pharmacy of the World’ to an innovation-led healthcare leader. It lays out a partnership-driven roadmap towards Viksit Bharat @2047, anchored in four priorities: better health for more people, resilient and trusted health systems, innovation-led economic value and global healthcare leadership.
 
The second report highlights the growing strategic importance of Global Capability Centres (GCCs) in India's pharmaceutical sector. With India hosting more than half of the world's GCC base, these centres are increasingly moving beyond routine delivery operations to take on critical enterprise functions.
 
The report identifies expanding GCC contributions across drug discovery, clinical development, pharmacovigilance, regulatory affairs, medical functions, market access, commercial operations, manufacturing and supply chains.
 
The third publication focuses on Regulatory Data Protection (RDP) and its potential role in accelerating pharmaceutical innovation and improving patient access. It explains how RDP differs from patents, centring on the protection of proprietary test and clinical trial data submitted to regulators to establish a medicine's safety and efficacy for marketing approval.
 
Government investment and regulatory reforms gain momentum
 
The summit also spotlighted India's efforts to strengthen its pharmaceutical innovation ecosystem through public investment, faster regulatory processes and digital transformation.
 
Senior government and regulatory stakeholders highlighted a significant reduction in the time lag between global and Indian launches of new medicines. The gap, which was around four to five years earlier, has narrowed to approximately six months or less in recent cases.
 
Government-backed funding is also gathering pace. The Rs 5,000 crore Promotion of Research and Innovation in Pharma-MedTech (PRIP) scheme has approved 49 projects, with around Rs 1,900 crore in government assistance and an expected Rs 3,500 crore in additional private investment.
 
Adding to the push, the Rs 10,000 crore BioPharma Shakti initiative, announced in the Union Budget 2026–27 for implementation over five years, aims to strengthen India's biologics and biosimilars ecosystem.
 
Regulatory digitalisation is another key area of progress, with nearly 95% of regulatory activities already digitised.
 
Building on the CDSCO's Sugam portal, the proposed Digital Drug Regulatory System aims to establish a single-window regulatory environment by integrating existing portals and incorporating emerging technologies, including artificial intelligence.
 
The summit also featured a panel discussion on ‘Power of Partnerships’, bringing together perspectives from across the pharmaceutical and healthcare ecosystem on the need to accelerate innovation and strengthen India's global competitiveness.
 
OPPI honours contributions to science and healthcare innovation
 
The OPPI Awards 2026 recognised individuals and organisations making significant contributions to science, healthcare and innovation.
 
Dr Habil F Khorakiwala received the OPPI Lifetime Achievement Award 2026, while Prof. (Dr.) Balram Bhargava was honoured with the OPPI Special Recognition Award 2026.
 
The other awardees included:
 
OPPI Scientist of the Year 2026: Prof. Aravind Penmatsa, Associate Professor, Molecular Biophysics Unit, Indian Institute of Science, Bangalore.
OPPI Woman Scientist of the Year 2026: Prof. Swati Biswas, Professor, Birla Institute of Technology & Science, Pilani.
OPPI Young Scientist of the Year 2026: Dr Jogender Singh, Assistant Professor, IISER, Mohali.
OPPI Excellence in Innovation Award for Healthcare Start-up of the Year 2026: Qure.ai.
 
As OPPI completes six decades of engagement with India's healthcare ecosystem, the summit reinforced a larger industry imperative: translating India's manufacturing strength into global scientific leadership.
 
The message emerging from the discussions was that sustained partnerships, predictable regulations, stronger research capabilities and continued investment will be critical to building a pharmaceutical ecosystem that delivers both global competitiveness and better health outcomes.

Upcoming E-conference

Other Related stories

Startup

Digitization

Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
Collaborative models are practical way to build capability in biologics: Manoj Kumar Panicker, Cytiva and Dr. Sanjib Banerjee, Veeda Lifesciences
(L-R) Manoj Kumar Panicker, General Manager, South Asia, Cytiva and Dr. Sanjib Banerjee, Chief Operating Officer (Biopharma Services), Veeda Lifesciences.